VEGFA and neoplasm: These strategies include tumor ECM disruption by ECM disruptors, such as matrix metalloproteinases11, hyaluronidase12, recombinant tissue plasminogen activator13, and tumor vessel normalization by vascular endothelial growth factor (VEGF) antibody bevacizumab14 and tyrosine kinase inhibitor (TKI) cediranib15, 16.